Optimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis
Open Access
- 1 February 2026
- journal article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-6
Abstract
Background: Pouchitis is the most common complication following ileal pouch-anal anastomosis for ulcerative colitis. Antibiotics remain the cornerstone of therapy for acute and chronic antibiotic dependent pouchitis, though evidence guiding their optimal use is limited. Material and Methods: A comprehensive literature search of PubMed, MEDLINE, Embase, and Google Scholar was conducted from database inception through October 2025 to identify studies evaluating antibiotic therapy for acute pouchitis. Eligible studies included randomized controlled trials, cohort studies, and observational series reporting clinical, endoscopic, or histologic outcomes. Data were extracted from 10 studies on study design, antibiotic regimen, efficacy, safety, and recurrence. Results: Data on the optimal selection of antibiotics for pouchitis is limited. Ciprofloxacin and metronidazole are the most extensively studied and commonly prescribed antibiotics. In a randomized clinical trial, ciprofloxacin demonstrated superior efficacy and tolerability compared with metronidazole. Rifaximin and vancomycin show potential benefit in selected cases. Conclusion: Antibiotic therapy provides rapid and effective symptom control in most patients with acute pouchitis. Ciprofloxacin should be considered first-line, with metronidazole or combination therapy reserved for non-responders.Keywords
This publication has 18 references indexed in Scilit:
- Pouchitis: pathophysiology and managementNature Reviews Gastroenterology & Hepatology, 2024
- Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort StudyClinical Gastroenterology and Hepatology, 2022
- Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch ConsortiumThe Lancet Gastroenterology & Hepatology, 2022
- Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch ConsortiumThe Lancet Gastroenterology & Hepatology, 2021
- Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2020
- Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot studyInflammatory Bowel Diseases, 2007
- Clostridium Difficile-Associated PouchitisDigestive Diseases and Sciences, 2006
- Differentiating risk factors for acute and chronic pouchitisClinical Gastroenterology and Hepatology, 2005
- Prospective Study of the Incidence, Timing, and Treatment of Pouchitis in 104 Consecutive Patients After Restorative ProctocolectomyArchives of Surgery, 1996
- Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitisDigestive Diseases and Sciences, 1994